2325 related articles for article (PubMed ID: 16545207)
1. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of Barrett's oesophagus: is it worthwhile?
Somerville M; Garside R; Pitt M; Stein K
Eur J Cancer; 2008 Mar; 44(4):588-99. PubMed ID: 18272361
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
4. Barrett's oesophagus: a review of costs of the illness.
Arguedas MR; Eloubeidi MA
Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
[TBL] [Abstract][Full Text] [Related]
5. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.
Kastelein F; van Olphen S; Steyerberg EW; Sikkema M; Spaander MC; Looman CW; Kuipers EJ; Siersema PD; Bruno MJ; de Bekker-Grob EW;
Gut; 2015 Jun; 64(6):864-71. PubMed ID: 25037191
[TBL] [Abstract][Full Text] [Related]
6. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance.
Gudlaugsdottir S; van Blankenstein M; Dees J; Wilson JH
Eur J Gastroenterol Hepatol; 2001 Jun; 13(6):639-45. PubMed ID: 11434588
[TBL] [Abstract][Full Text] [Related]
7. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
[TBL] [Abstract][Full Text] [Related]
8. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma.
Sonnenberg A; Soni A; Sampliner RE
Aliment Pharmacol Ther; 2002 Jan; 16(1):41-50. PubMed ID: 11856077
[TBL] [Abstract][Full Text] [Related]
9. Treatment for Barrett's oesophagus.
Rees JR; Lao-Sirieix P; Wong A; Fitzgerald RC
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD004060. PubMed ID: 20091557
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin.
Fayter D; Corbett M; Heirs M; Fox D; Eastwood A
Health Technol Assess; 2010 Jul; 14(37):1-288. PubMed ID: 20663420
[TBL] [Abstract][Full Text] [Related]
11. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett's oesophagus in the United Kingdom.
Pollit V; Graham D; Leonard C; Filby A; McMaster J; Mealing SJ; Lovat LB; Haidry RJ
Curr Med Res Opin; 2019 May; 35(5):805-815. PubMed ID: 30479169
[TBL] [Abstract][Full Text] [Related]
13. Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations.
Hirst NG; Gordon LG; Whiteman DC; Watson DI; Barendregt JJ
J Gastroenterol Hepatol; 2011 Feb; 26(2):247-54. PubMed ID: 21261712
[TBL] [Abstract][Full Text] [Related]
14. [Surveillance for Barrett's oesophagus: worthwhile?].
Kastelein F; Kuipers EJ
Ned Tijdschr Geneeskd; 2012; 156(49):A5497. PubMed ID: 23218039
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
17. Should patients with Barrett's oesophagus be kept under surveillance? The case for.
Armstrong D
Best Pract Res Clin Gastroenterol; 2008; 22(4):721-39. PubMed ID: 18656826
[TBL] [Abstract][Full Text] [Related]
18. A surveillance programme for Barrett's oesophagus in a UK general hospital.
Olithselvan A; Gorard DA; McIntyre AS
Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile?
Somerville M; Pitt M
Frontline Gastroenterol; 2010 Jul; 1(2):88-93. PubMed ID: 28839554
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]